|Day Low/High||1.66 / 1.79|
|52 Wk Low/High||1.19 / 3.33|
Idera receives $15 million upfront, with potential IMO-9200-related milestone payments totaling up to $140 million plus royalties
Our screen reveals 17 names that could become oversold and disconnected from their fundamentals as a result of this phenomenon.
Insiders at these companies are scooping up shares of their own stock lately.
Presentation to be made at Cold Springs Harbor Laboratory Conference on Regulatory & Non-Coding RNAs
Investors considering a purchase of Idera Pharmaceuticals Inc shares, but tentative about paying the going market price of $2.00/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2017 put at the $1 strike, which has a bid at the time of this writing of 10 cents.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
These stocks are poised to break out and trade higher from current levels.
Investors in Idera Pharmaceuticals Inc saw new options become available this week, for the March 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IDRA options chain for the new March 18th contracts and identified the following call contract of particular interest.
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a weak on high relative volume candidate